Benztropine is an anticholinergic agent used predominantly in the symptomatic therapy of Parkinson disease and movement disorders. Benztropine has not been associated with serum enzyme elevations during treatment and must be a very rare cause of clinically apparent acute liver injury, if it occurs at all.
Benztropine (benz' troe peen) is an anticholinergic agent that blocks the central cholinergic receptors helping to balance cholinergic transmission in the basal ganglia. Benztropine may also block dopamine reuptake and storage in central sites thus increasing dopaminergic activity. The exact mechanism(s) by which the anticholinergic agents are beneficial for symptoms of Parkinson disease is unknown. They are used largely in early Parkinsonism and as adjunctive therapy with levodopa or more potent antiParkinson disease agents. Benztropine was approved for use in the United States in 1954 and has been in common use since. Current indications include therapy of symptomatic Parkinson’s disease as well as drug induced extrapyramidal syndromes. Benztropine in parenteral forms is also used for therapy of acute dystonic reactions. Benztropine is available in tablets of 0.5, 1 and 2 mg, and in liquid solution for injection (2 mL ampoules; 1 mg/mL) in generic forms and under the brand name of Cogentin. The recommended dose is 0.5 to 6 mg daily. Common side effects are due to its anticholinergic activity and include nervousness, drowsiness, confusion, tachycardia, blurred vision, constipation, dry mouth, nausea and urinary retention.
|DRUG||CAS REGISTRY NUMBER||MOLECULAR FORMULA||STRUCTURE|
Top of page